Across TCGA pan-cancer cohorts, ALPK3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ALPK3 data layer compared with 26 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALPK3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALPK3 expression acts as an unfavorable survival marker.
LUAD and PDAC are the cancer types where ALPK3 mass-spec protein most reproducibly stratifies survival.